Dott. Giancarlo Comi

• Professore Ordinario di Neurologia, Università Vita-Salute San Raffaele

• Dal 2001: Direttore Scientifico del Centro SM, Ospedale San Raffaele
• Dal 2002: Direttore Scientifico del Centro Studi Sclerosi Multipla, Az. Ospedaliera “S. Antonio Abate” di Gallarate
• Dal 2004: Direttore Scientifico, Istituto di Neurologia Sperimentale (INSPE), Ospedale San Raffaele
• Dal 2008: Direttore, Dipartimento di Neurologia, Ospedale San Raffaele

ATTIVITÀ SCIENTIFICA E PUBBLICAZIONI

• Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H-P, Seeldrayers P, Soelberg Sorensen P, Rovaris M, Martinelli V, Hommes O.R, and the early treatment of multiple sclerosis study group.Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357:1576-1582 IF:13.251
• Comi G, Filippi M, Wolinsky J and the European/Canadian glatiramer acetate study group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured disease activity and burden in patients with relapsing Multiple Sclerosis. Ann Neurol 2001;49:290-297 I.F. 8.481
• Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, Karageorgiu C, Nobile-Orazio E, Van Den Berg P, Swan T, Hughes R, and the inflammatory neuropathy cause and treatment (INCAT) Group; A randomised controlled trial of intravenous immunolobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002; 249:1370-1377. IF 2.653
• Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Del Carro U, Amadio S, Bergami A, Furlan R, Comi G, Vescovi A, Martino G. Injection of adult neurspheres induces recovery in a chronic model of multiple sclerosis. Nature 2003;422:688-694. IF 30.979
• Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G, Martinello M, Cattalini A, Bergami A, Furlan R, Comi G, Constantin G, Martino G. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005; 436; 266-271. IF. 32.182
• Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj Kw, Sharrack B, Filippi M, for the LAQ/5062 Study Group. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase Iib study. Lancet 2008;371:2085-2092. IF 28.409
• Comi G. Clinically isolated sindrome: the rationale for early treatment. Nat Clin Pract Neuro 2008;4:234-235. IF 6.979
• Comi G. Treatment of multiple sclerosis: role of natalizumab. Neurol Sci 2009;Suppl 2:S155-158. IF 1.435
• Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung H, Hiillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr K, Ravnborg M, Rieckmann P, Wynn D, Young C, Fiilippi M; for the PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo-controlled trial. Lancet 2009;374(9700):1503-1511. IF 28.409
• Comi G, O’Connor P, Montalban X, Antel J, Radue Ew, Karlsson G, Pohlmann H, Aradhye S, Kappos L. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2009. IF 3.312
• Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 2009;31:1142-1157. IF 3.064
• O’Connor P, Comi G, Montalban X, Antel J, Radue Ew, De Vera A, Pohlmann H, Kappos L, Fty720 D2201 Study Group. Oral Fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72(1):73-79. IF 7.043
• O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung Hp, Jefferey D, Kappos L, Boateng F, Fiilippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumill T; for the BEYOND Study Group. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;889-897. IF 14.270
• Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg Sj, For the CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362(5):456-458. IF 50.017

• Sclerosi multipla